Recent Updates
Recently added Catalysts
ALVO Negative Sentiment Score: 25/100

ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Alvotech on behalf of its stockholders following a Complete Response Letter from the FDA regarding its AVT05 BLA. This letter was issued after a failed facility inspection in July 2025. As a result of this negative news, Alvotech's stock plummeted by over 34%. Shareholders who have experienced losses are being encouraged to contact the firm to discuss potential legal options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Alvotech received a Complete Response Letter from the FDA regarding its AVT05 BLA, indicating regulatory challenges.
  • A failed facility inspection in July 2025 has triggered the investigation and resulted in significant stock loss.
  • Alvotech's stock fell by $2.62, or 34.25%, following the announcement, indicating loss of shareholder confidence.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alvotech (ALVO) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Alvotech stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Alvotech (“Alvotech” or the “Company”) (NASDAQ:ALVO) on behalf of Alvotech stockholders. Our investigation concerns whether Alvotech has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On November 3, 2025, Alvotech received a Complete Response Letter from the FDA regarding its AVT05 BLA biologics license application following a failed facility inspection in July 2025. On this news, Alvotech’s stock fell $2.62, or 34.25%, to close at $5.03 per share.
If you purchased or otherwise acquired Alvotech shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

What should Alvotech investors do if they suffered losses?

Investors who lost money in Alvotech should contact Brandon Walker or Marion Passmore.

What prompted the investigation into Alvotech?

The investigation follows Alvotech receiving a Complete Response Letter from the FDA.

How much did Alvotech's stock drop after the FDA announcement?

Alvotech's stock fell by $2.62, a 34.25% decrease, closing at $5.03.

Is there a cost to discuss claims with Bragar Eagel & Squire?

No, there is no cost or obligation to discuss claims with the law firm.

Where is Bragar Eagel & Squire located?

The firm has offices in New York, South Carolina, and California.

Last updated: Nov 5, 2025